CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alkermes, Inc. (Nasdaq: ALKS) today announced that the Japanese organization of its partner Janssen-Cilag, Janssen Pharmaceutica K.K., submitted a new drug application to the Pharmaceuticals and Medical Devices Agency (PMDA) for marketing approval in Japan of RISPERDAL® CONSTA® [(risperidone) long-acting injection], an atypical antipsychotic medication for the treatment of schizophrenia. RISPERDAL CONSTA is the first and only long-acting, atypical antipsychotic approved by the U.S. Food and Drug Administration and now is approved in more than 70 countries worldwide.
